According to Spectrum Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.21654. At the end of 2023 the company had a P/S ratio of 6.27.
Year | P/S ratio | Change |
---|---|---|
2023 | 6.27 | -15.38% |
2022 | 7.40 | |
2021 | N/A | |
2020 | N/A | |
2019 | N/A | -100% |
2018 | 8.85 | -40.48% |
2017 | 14.9 | 509.8% |
2016 | 2.44 | -3.71% |
2015 | 2.53 | 3.43% |
2014 | 2.45 | -32.78% |
2013 | 3.64 | 7.7% |
2012 | 3.38 | -22.35% |
2011 | 4.35 | -8.75% |
2010 | 4.77 | -16.51% |
2009 | 5.71 | 286.02% |
2008 | 1.48 | -86.63% |
2007 | 11.1 | -52.28% |
2006 | 23.2 | -82.22% |
2005 | 130 | 66.23% |
2004 | 78.5 | 265.97% |
2003 | 21.4 | 936.47% |
2002 | 2.07 | -99.9% |
2001 | > 1000 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 3.78 | -54.05% | ๐บ๐ธ USA |
Novartis NVS | 3.71 | -54.86% | ๐จ๐ญ Switzerland |
Pfizer PFE | 2.46 | -70.09% | ๐บ๐ธ USA |
Abbott Laboratories ABT | 4.55 | -44.57% | ๐บ๐ธ USA |
Biogen BIIB | 2.82 | -65.73% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 2.18 | -73.53% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2.15 | -73.88% | ๐ฌ๐ง UK |
Seagen
SGEN | 18.8 | 128.32% | ๐บ๐ธ USA |
Curis CRIS | 8.95 | 8.93% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | 0.9135 | -88.88% | ๐ฎ๐ฑ Israel |